Amgen Inc. (AMGN) 주식 — 좋은 사업일까?

Amgen Inc. (AMGN) 주식 — 좋은 사업일까? — InspectStocks

Just reported

Q3 2026 results

From Amgen's results release of 2026년 11월 3일; its quarterly report has since been filed.

Revenue
Actual
US$10.37B
+8.5% y/y
+3.1% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$7.08
+19% y/y
+62% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$3.71B
+47% y/y
+5.6% q/q
Guided
—
No guide given

Company outlook

Full year 2026

RevenueUS$38.9B – US$39.7B+6.9% y/y Raised +1.3%
EPS, adjustedUS$22.90 – US$23.70Raised +1.7%
EPS, GAAPUS$18.34 – US$19.28+32% y/y Raised +14%

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

어떻게 돈을 버는가

Repatha prescription sales9%
Otezla prescription sales7%
Enbrel prescription sales7%
EVENITY prescription sales7%
XGEVA prescription sales6%
TEPEZZA prescription sales6%

매출 비중은 year ended 2025-12-31, high confidence 기준 추정치이며, 제출된 보고서의 수치가 아닙니다.

경쟁 상대

무엇을 파는가6

Repatha
An injectable medicine that lowers LDL cholesterol and is used to reduce the chance of major heart and blood-vessel events in certain adults.
Prolia
A medicine for osteoporosis that helps reduce fracture risk in certain people, including postmenopausal women and men at high risk of fracture.
Otezla
An oral medicine used for plaque psoriasis, psoriatic arthritis and certain mouth ulcers.

3개 더 보기

ENBREL
A medicine used for rheumatoid arthritis, plaque psoriasis and psoriatic arthritis.
TEZSPIRE
An antibody medicine used as an add-on treatment for severe uncontrolled asthma and, in approved markets, chronic sinus inflammation with nasal polyps.
IMDELLTRA
A cancer medicine for adults with extensive-stage small cell lung cancer that has progressed during or after platinum-based chemotherapy.

누가 사는가3

In the United States, Amgen sells substantially all its products to pharmaceutical wholesalers, which then distribute them to healthcare providers. McKesson, Cencora and Cardinal Health together accounted for 77% of worldwide gross revenue (year ended 2025-12-31, high confidence).
Outside the United States, Amgen sells to healthcare providers and pharmaceutical wholesalers, depending on local distribution practices.
Healthcare providers, including physicians and their clinics, hospitals, dialysis centers and pharmacies, use or dispense Amgen medicines; some products are also marketed through direct-to-patient channels.

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

1Amgen relies on large wholesalers for distribution: McKesson, Cencora and Cardinal Health together accounted for 77% of worldwide gross revenue (year ended 2025-12-31, high confidence).
2The United States is its largest market, accounting for 71.9% of revenue by geography (year ended 2025-12-31, high confidence).
3Its sales depend on government and commercial insurers covering its medicines and deciding how much they will reimburse; coverage rules and required discounts can affect use and net prices.
4The 10-K says a substantial majority of commercial manufacturing takes place in Puerto Rico and a substantial majority of clinical manufacturing takes place in Thousand Oaks, California.
5Amgen relies on third-party suppliers for some raw materials, devices and components, including items for which a supplier may be its only source.

잘못될 수 있는 일

1Government and private payer policies can limit access or reduce the prices Amgen receives. The filings describe Medicare price setting for ENBREL and Otezla, expanded discounts through the 340B program, and other pricing policies as pressures on sales and profitability.
2Biosimilar and generic competition can reduce sales and prices. The patents for Prolia and XGEVA have expired in key markets, and the 10-Q reports lower sales as biosimilar competitors entered those markets.
3Manufacturing disruption could limit medicine supply and sales. The 10-K identifies concentration of commercial manufacturing in Puerto Rico and clinical manufacturing in Thousand Oaks, California, as potential sources of disruption.

전체 재무제표 보기 →

Amgen Inc. 소개

Amgen researches, develops and manufactures medicines, including biologic medicines made using living cells and small-molecule drugs. It sells treatments for conditions including heart disease, cancer, osteoporosis, asthma and autoimmune diseases. It also sells biosimilar medicines, which are highly similar versions of existing biologic medicines.

본사: Thousand Oaks, California
설립: 1980 (incorporated in California; high confidence)
상장 시장: NASDAQ
회계연도 종료: December 31

Amgen Inc.이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.

Just reported

Q3 2026 results

From Amgen's results release of 2026년 11월 3일; its quarterly report has since been filed.

Revenue
Actual
US$10.37B
+8.5% y/y
+3.1% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$7.08
+19% y/y
+62% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$3.71B
+47% y/y
+5.6% q/q
Guided
—
No guide given

Company outlook

Full year 2026

RevenueUS$38.9B – US$39.7B+6.9% y/y Raised +1.3%
EPS, adjustedUS$22.90 – US$23.70Raised +1.7%
EPS, GAAPUS$18.34 – US$19.28+32% y/y Raised +14%

Keep exploring

The themes Amgen is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The themes it is part of

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

All 19 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

어떻게 돈을 버는가

Repatha prescription sales9%
Otezla prescription sales7%
Enbrel prescription sales7%
EVENITY prescription sales7%
XGEVA prescription sales6%
TEPEZZA prescription sales6%

매출 비중은 year ended 2025-12-31, high confidence 기준 추정치이며, 제출된 보고서의 수치가 아닙니다.

경쟁 상대

무엇을 파는가6

Repatha
An injectable medicine that lowers LDL cholesterol and is used to reduce the chance of major heart and blood-vessel events in certain adults.
Prolia
A medicine for osteoporosis that helps reduce fracture risk in certain people, including postmenopausal women and men at high risk of fracture.
Otezla
An oral medicine used for plaque psoriasis, psoriatic arthritis and certain mouth ulcers.

3개 더 보기

ENBREL
A medicine used for rheumatoid arthritis, plaque psoriasis and psoriatic arthritis.
TEZSPIRE
An antibody medicine used as an add-on treatment for severe uncontrolled asthma and, in approved markets, chronic sinus inflammation with nasal polyps.
IMDELLTRA
A cancer medicine for adults with extensive-stage small cell lung cancer that has progressed during or after platinum-based chemotherapy.

누가 사는가3

In the United States, Amgen sells substantially all its products to pharmaceutical wholesalers, which then distribute them to healthcare providers. McKesson, Cencora and Cardinal Health together accounted for 77% of worldwide gross revenue (year ended 2025-12-31, high confidence).
Outside the United States, Amgen sells to healthcare providers and pharmaceutical wholesalers, depending on local distribution practices.
Healthcare providers, including physicians and their clinics, hospitals, dialysis centers and pharmacies, use or dispense Amgen medicines; some products are also marketed through direct-to-patient channels.

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

1Amgen relies on large wholesalers for distribution: McKesson, Cencora and Cardinal Health together accounted for 77% of worldwide gross revenue (year ended 2025-12-31, high confidence).
2The United States is its largest market, accounting for 71.9% of revenue by geography (year ended 2025-12-31, high confidence).
3Its sales depend on government and commercial insurers covering its medicines and deciding how much they will reimburse; coverage rules and required discounts can affect use and net prices.
4The 10-K says a substantial majority of commercial manufacturing takes place in Puerto Rico and a substantial majority of clinical manufacturing takes place in Thousand Oaks, California.
5Amgen relies on third-party suppliers for some raw materials, devices and components, including items for which a supplier may be its only source.

잘못될 수 있는 일

1Government and private payer policies can limit access or reduce the prices Amgen receives. The filings describe Medicare price setting for ENBREL and Otezla, expanded discounts through the 340B program, and other pricing policies as pressures on sales and profitability.
2Biosimilar and generic competition can reduce sales and prices. The patents for Prolia and XGEVA have expired in key markets, and the 10-Q reports lower sales as biosimilar competitors entered those markets.
3Manufacturing disruption could limit medicine supply and sales. The 10-K identifies concentration of commercial manufacturing in Puerto Rico and clinical manufacturing in Thousand Oaks, California, as potential sources of disruption.

전체 재무제표 보기 →

Amgen Inc. 소개

본사: Thousand Oaks, California
설립: 1980 (incorporated in California; high confidence)
상장 시장: NASDAQ
회계연도 종료: December 31

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

어떻게 돈을 버는가

경쟁 상대

무엇을 파는가6

누가 사는가3

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

잘못될 수 있는 일

Amgen Inc. 소개

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Keep exploring

The themes it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

어떻게 돈을 버는가

경쟁 상대

무엇을 파는가6

누가 사는가3

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

잘못될 수 있는 일

Amgen Inc. 소개

Keep exploring

The themes it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Big pharma

Amgen Inc.

성장과 현금 — 5개 중 5개

사업 추세

주가와 등급 추이

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

어떻게 돈을 버는가

경쟁 상대

무엇을 파는가6

누가 사는가3

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

잘못될 수 있는 일

Amgen Inc. 소개

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Keep exploring

The themes it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

어떻게 돈을 버는가

경쟁 상대

무엇을 파는가6

누가 사는가3

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

잘못될 수 있는 일

Amgen Inc. 소개

Keep exploring

The themes it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Big pharma

Amgen Inc.

과거 수익률

성장과 현금 — 5개 중 5개

사업 추세

주가와 등급 추이